Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.54 |
| ▸ | PLD1 | Q13393 | 4/20 | 0.48 |
| ▸ | PLD2 | O14939 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8203000 | 0.93 | SIGMAR1 (0.48) | SIGMAR1PLD1PLD2ALDH1A1 | |
| SCHEMBL13054004 | 0.93 | SIGMAR1 (0.48) | SIGMAR1PLD1PLD2ALDH1A1 | |
| SCHEMBL7563203 | 0.93 | SIGMAR1 (0.48) | SIGMAR1PLD1PLD2ALDH1A1 | |
| SCHEMBL7569678 | 0.81 | DEGS1 (0.49) | SIGMAR1ALDH1A1 | |
| SCHEMBL13054426 | 0.81 | DEGS1 (0.49) | SIGMAR1ALDH1A1 | |
| SCHEMBL8202126 | 0.78 | ACKR3 (0.50) | SIGMAR1ALDH1A1 | |
| SCHEMBL7571867 | 0.78 | ACKR3 (0.50) | SIGMAR1ALDH1A1 | |
| SCHEMBL13440511 | 0.75 | SIGMAR1 (0.47) | SIGMAR1 | |
| SCHEMBL7545591 | 0.75 | SIGMAR1 (0.47) | SIGMAR1 | |
| SCHEMBL7600803 | 0.75 | NAMPT (0.52) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120231017-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | PHARMACOPEIA INC. (US) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120231017-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | BACE1, PRSS1, TMPRSS11D | SIGMAR1 3119/4885PLD1 369/4885PLD2 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.